Package Leaflet: Information for the User
FIRDAPSE 10 mg Tablets
amifampridine
This medicinal product is subject to additional monitoring, which will allow for the quick detection of new safety information. You can help by reporting any side effects you may experience. The last section of section 4 will provide information on how to report side effects.
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the Package Leaflet
FIRDAPSE is used to treat the symptoms of a nerve and muscle disease called Lambert-Eaton myasthenic syndrome (LEMS) in adults. It is a disorder that affects the transmission of nerve impulses to muscles, causing muscle weakness. It can be associated with certain types of tumors (paraneoplastic LEMS) or occur in the absence of tumors (non-paraneoplastic LEMS).
In patients with this disease, a chemical substance called acetylcholine, which transmits nerve impulses to muscles, is not released normally, and the muscle stops receiving some or all of the nerve signals.
FIRDAPSE works by increasing the release of acetylcholine and helping the muscle receive nerve signals.
Do not take FIRDAPSE
If you have any doubts, consult your doctor or pharmacist.
Warnings and precautions
Consult your doctor or pharmacist before starting to take FIRDAPSE.
Tell your doctor if you have:
Your doctor will closely monitor your response to FIRDAPSE and may need to adjust the dose of the medicines you are taking. Your doctor will also monitor your heart at the start of treatment and then once a year.
If you have LEMS but no cancer, your doctor will carefully assess the possible risk of you developing cancer with FIRDAPSE before starting treatment.
Tell any doctor you consult that you are using FIRDAPSE.
Stop treatment and consult your doctor immediately if:
Taking FIRDAPSE with other medicines
Tell your doctor if you are taking, have recently taken, or might take any other medicines.
Some medicines may interact with FIRDAPSE if taken together. The following medicines should not be combined with FIRDAPSE:
It is especially important that you tell your doctor if you are taking any of the following medicines or plan to start taking them:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
You should not use FIRDAPSE if you are pregnant. You will need to use an effective method of contraception during the entire treatment period. If you become pregnant during treatment, tell your doctor immediately.
It is not known whether FIRDAPSE is excreted in human breast milk. You and your doctor will need to weigh the benefits and risks of continuing to take FIRDAPSE during breastfeeding.
Driving and using machines
This medicine may cause drowsiness, dizziness, epileptic seizures (convulsions), and blurred vision, which could affect your ability to drive or use machines. Do not drive or use machines if you experience these side effects.
Follow the instructions for administration of this medicine exactly as told by your doctor.
If you are unsure, consult your doctor or pharmacist again.
Your doctor will tell you the dose you should take based on the severity of your symptoms and certain genetic factors. This dose will be suitable only for you.
The initial dose is 5 mg of amifampridine (half a tablet) three times a day (i.e., 15 mg per day). Your doctor may increase this dose gradually, first to 5 mg (half a tablet) four times a day (i.e., 20 mg per day). Then, your doctor may continue to increase your total daily dose by adding 5 mg (half a tablet) per day, every 4 or 5 days.
The maximum recommended dose is 60 mg per day (i.e., a total of six tablets taken at intervals throughout the day). Daily doses above 20 mg should be divided into two to four separate doses. No more than 20 mg should be taken in a single dose (two tablets).
The tablets have a score line that allows them to be broken in half. The tablets should be swallowed with a little water and taken with food.
Patients with liver or kidney problems:
FIRDAPSE should be used with caution in patients with kidney or liver problems. A starting dose of 5 mg (half a tablet) of FIRDAPSE per day is recommended in patients with moderate or severe kidney or liver problems. In patients with mild kidney or liver problems, a starting dose of 10 mg (5 mg twice a day) of FIRDAPSE is recommended. In these patients, the dose of FIRDAPSE should be increased more slowly than in patients without liver or kidney problems, with increments of 5 mg every 7 days. If you experience any side effects, consult your doctor, as you may need to stop increasing the dose.
If you take more FIRDAPSE than you should
If you take more FIRDAPSE than you should, you may experience vomiting or stomach pain. If you experience any of these symptoms, contact your doctor or pharmacist immediately.
If you forget to take FIRDAPSE
If you forget to take FIRDAPSE, do not take a double dose to make up for the missed doses; continue taking the treatment as instructed by your doctor.
If you stop treatment with FIRDAPSE
If you stop treatment, you may experience symptoms such as fatigue, slow reflexes, and constipation. Do not stop treatment without consulting your doctor.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop treatment and consult your doctor immediately if:
Very common side effects that may affect more than 1 in 10 people are:
Common side effects that may affect up to 1 in 10 people are:
Other side effects are:
The intensity and incidence of most side effects depend on the dose you are taking. The following side effects have also been reported (frequency cannot be estimated from the available data):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
Do not store above 30°C. Store in the original package to protect from light and moisture.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of FIRDAPSE
Appearance of the product and pack contents
White, round, flat on one side and scored on the other side tablet.
The tablets can be divided into two equal halves.
Thermoformed unit dose blisters (aluminum-PVC/PVDC laminated blisters) with 10 tablets.
A carton contains 100 tablets in 10 strips of 10 tablets each.
Marketing authorization holder and manufacturer
Marketing authorization holder:
BioMarin International Limited
Shanbally, Ringaskiddy
County Cork, P43 R298
Ireland
Manufacturers:
EXCELLA GmbH & Co. KG
Nürnberger Strasse 12
90537 Feucht
Germany
BioMarin International Limited
Shanbally, Ringaskiddy, Co. Cork, P43 R298
Ireland
Date of last revision of this leaflet:MM/AAAA
This medicine has been authorized under "exceptional circumstances".
This means that due to the rarity of your disease, it has not been possible to obtain complete information on this medicine.
The European Medicines Agency will review any new information that may become available every year and this leaflet will be updated as necessary.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.